intractable partial onset epilepsy
Neurology · 2017–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brivaracetam Treatment of intractable partial onset epileptic seizures in combination with other anti-epileptic drugs, as an add-on therapy in children aged 4-15 years… | Nov 2019 | Recommended with restriction | input received |
| lacosamide Extension of existing listing for intractable partial onset epileptic seizures in combination with two or more anti-epileptic drugs, to include patients aged… | Nov 2018 | Recommended with restriction | input received |
| brivaracetam Add-on therapy for intractable partial onset epileptic seizures in patients aged 16 years or older, in combination with two or more anti-epileptic drugs… | Mar 2017 | Not recommended | input received Epilepsy Action Australia · Epilepsy Foundation |
| brivaracetam Treatment of intractable partial onset epileptic seizures as add-on therapy in patients aged 16 years or older who have failed to be controlled satisfactorily… | Nov 2017 | Recommended with restriction | none received |
Who spoke
Epilepsy Action Australia · Epilepsy Foundation
What the PBS pays
$24M in government benefit over 2024–25, across 181,129 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lacosamide | $15M |
| brivaracetam | $8.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.